Fuji Pharma Co Ltd 2024 IR
The report outlines Fuji Pharma's strategic progress during the fiscal year ended September 30, 2023, highlighting its transition into a specialty pharmaceutical company focused on women's healthcare and biosimilars. The company achieved record consolidated net sales of 40.9 billion yen, driven by strong performance in infertility and menopausal treatments. Key milestones include the completion of the sixth drug production building at the Toyama Plant to triple hormone tablet capacity and the manufacturing approval of its first biosimilar, USTEKINUMAB BS. Additionally, the company advanced its sustainability initiatives, earning a Silver Medal in the EcoVadis assessment for the second consecutive year and introducing offsite solar power purchase agreements to support its carbon neutrality goals.
Company: Fuji Pharma Co Ltd
Sector: Health Care
Country: Japan
Year: 2024
Type: IR
Pages: 29
Fuji Pharma Co Ltd
Corporate Report
The report outlines Fuji Pharma's strategic progress during the fiscal year ended September 30, 2023, highlighting its transition into a specialty pharmaceutical company focused on women's healthcare and biosimilars. The company achieved record consolidated net sales of 40.9 billion yen, driven by strong performance in infertility and menopausal treatments. Key milestones include the completion of the sixth drug production building at the Toyama Plant to triple hormone tablet capacity and the manufacturing approval of its first biosimilar, USTEKINUMAB BS. Additionally, the company advanced its sustainability initiatives, earning a Silver Medal in the EcoVadis assessment for the second consecutive year and introducing offsite solar power purchase agreements to support its carbon neutrality goals.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Oct 1, 2022 - Sep 30, 2023
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Women on Board
Women in Management
Net Zero Target
Employees